Clinical Trials Logo
  1. Home
  2. X-linked Adrenoleukodystrophy
  3. NCT04687007

SMART-ALD - A New Lifestyle Intervention to Improve Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD)

X-linked Adrenoleukodystrophy Clinical Trial

Official title:
SMART-ALD - A New Lifestyle Intervention to Improve Physical and Mental Well-being and Quality of Life in Women With X-linked Adrenoleukodystrophy (X-ALD)

Clinical Trial Summary

X-linked Adrenoleukodystrophy (X-ALD) is one of the most frequent inborn error of metabolism caused by mutations in the ABCD1 gene, which codes for the transporter of saturated very long-chain fatty acids (VLCFA) for peroxisomal degradation, thus causing their toxic accumulation in body fluids and tissues. The clinical spectrum ranges from adrenal insufficiency without neurological symptoms to a rapidly progressive, fatal cerebral demyelinating disease that may occur in childhood as well as later in life. The most frequent phenotype in adulthood is adrenomyeloneuropathy (AMN), a slowly progressive myelopathy and peripheral neuropathy, which may also be prevalent in up to 80% of females carrying the X-ALD gene defect. Since signs and symptoms in females are usually milder and with a later onset, they are frequently underestimated, overlooked or misinterpreted, e.g. as Multiple Sclerosis. Consequently, many women with X-ALD do not receive adequate treatment. Against this background, the development of new therapeutic interventions with the help of eHealth technology (e.g., counselling and treatment via digital communication tools) is of particular relevance, as it provides cost-effective, regular care even for patients who live remote from Leukodystrophy clinics. The aims of this study is to evaluate the effectiveness of a multi-approach intervention ("SMART-ALD") on physical and mental well-being and quality of life in n=30 X-ALD symptomatic heterozygous females compared to a waiting list control group (n=30) using electronic health (ehealth) technology.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04687007
Study type Interventional
Source Leipzig University Medical Center
Contact
Status Completed
Phase N/A
Start date May 20, 2022
Completion date February 1, 2024
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05911919 - Validation of a Prognostic Biomarker Using Brain Diffusion MRI in X-linked Adrenoleukodystrophy
Recruiting NCT03727555 - Lentiviral Gene Therapy for X-ALD N/A
Completed NCT02595489 - A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy Phase 1
Completed NCT01594853 - Exercise Study of Function and Pathology for Women With X-linked Adrenoleukodystrophy N/A
Completed NCT01165060 - The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD) N/A
Recruiting NCT05939232 - Registry of X-linked Adrenoleukodystrophy
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Completed NCT03864523 - Effect of Pioglitazone Administered to Patients With Adrenomyeloneuropathy Phase 2
Recruiting NCT06178120 - Disease Progression in Women With X-linked Adrenoleukodystrophy
Recruiting NCT03278899 - A Study to Prospectively Assess Disease Progression in Male Children With X-ALD
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04675749 - Quality of Life in Women With X-linked Adrenoleukodystrophy
Withdrawn NCT03196765 - Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy Phase 1/Phase 2
Withdrawn NCT01787578 - Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD) Phase 1
No longer available NCT02233257 - Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy N/A